Xenetic Biosciences updates investor presentation on Santersus share exchange, outlines pro forma valuation and 2027—2029 milestones

Xenetic Biosciences released an updated investor presentation on its proposed share exchange with Santersus, outlining an illustrative ~85%/15% pro—forma ownership split, estimated $141M valuation for Santersus and key clinical and regulatory milestones through 2029.Key Highlights:Original SEC Fili…